Magnetically modulated nanosystems: A unique drug-delivery platform

Nanomedicine

Volumn 4, Issue 7, 2009, Pages 799-812

  Barakat, Nahla S ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Contrast agent; Drug delivery system; Hyperthermia; Magnetic nanoparticles; MRI; Nanoparticle functionalization; Synthesis methods; Tissue engineering

Indexed keywords

DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; MAGNETIC NANOPARTICLE; METAL NANOPARTICLE; POLYOL;

ANTINEOPLASTIC ACTIVITY; BIOCOMPATIBILITY; BIOTECHNOLOGY; BODY FLUID; CANCER THERAPY; CARDIOTOXICITY; CELL SEPARATION; DECOMPOSITION; DETOXIFICATION; DNA EXTRACTION; DRUG COATING; DRUG DELIVERY SYSTEM; GENE DELIVERY SYSTEM; GENE TARGETING; HUMAN; HYPERTHERMIA; IMMUNOASSAY; LUNG; MAGNETIC FIELD; MAGNETIC SEPARATION; MAGNETOSOME; MICROEMULSION; MUSCULOSKELETAL SYSTEM; NANOMEDICINE; NANOSYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; TISSUE ENGINEERING;

DRUG DELIVERY SYSTEMS; HUMANS; MAGNETICS; METAL NANOPARTICLES; MODELS, THEORETICAL; NANOTECHNOLOGY;

EID: 73549085391     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.09.66     Document Type: Review

References (98)

1. Torchilin VP: Drug targeting. Eur. J. Pharm. Sci. 11, S81-S91 (2000).
2. Etrych T, Jelinkova M, Rihova B, Ulbrich K: New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties. J. Contr. Rel. 73, 89-102 (2001).
3. Eeckman F, Moes AJ, Amighi K: Evaluation of a new controlleddrug delivery concept based on the use of thermoresponsive polymers. Int. J. Pharm. 241, 113-125 (2002).
4. Liu SQ, Tong YW, Yang YY: Incorporation and in vitro release of doxorubicin in thermally sensitive micelles made from poly (N-isopropylacrylamide-co-N, N-dimethylacrylamide)-b-poly (D,L-lactide-co-glycolide) with varying compositions. Biomaterials 26, 5064-5074 (2005).
5. Sunderland CJ, Steiert M, Talmadge JE, Derfus AM, Barry SE: Targeted nanoparticles for detecting and treating cancer. Drug Dev. Res. 67, 70-93 (2006).
6. Widder KJ, Marino PA, Morris RM, Senyei AE: In: Targeted Drugs. Goldberg E (Ed.). John Wiley and Sons, NY, USA, 201 (1983). 7 Brannon-Peppas L, Blanchette JO: Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 56, 1649-1673 (2004).
7. Lubbe AS, Alexiou C, Bergemann C: Clinical application of magnetic drug targeting. J. Surg. Res. 95, 200-206 (2001).
8. Hu SH, Liu TY, Liu DM, Chen SY: Nano-ferrosponges for controlled drug release. J. Control. Rel. 121, 181-198 (2007).
9. Lacava LM, Lacava ZGM, Da Silva MF et al.: Magnetic resonance of a dextran-coated magnetic fluid intravenously administered in mice. Biophys. J. 80, 2483-2486 (2001).
10. Jeong YII, Seo SJ, Park IK et al.: Cellulor recognition of paclitaxel-laded polymeric nanoparticles composed of poly(Y-benzyl I-glutamiate) and poly(ethylene glycol) diblock copolymer endcapped with galactose moiety. Int. J. Pharm. 296, 151-161 (2005).
11. Davis SS: Biomedical applications of nanotechnology - implications for drug targeting and gene therapy. Trends Biotechnol. 15, 217-224 (1997).
12. Ferrari M: Nanovector therapeutics. Curr. Opin. Chem. Biol. 9, 343-346 (2005).
13. Yamaoka T, Tabata Y, Ikada Y: Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J. Pharm. Sci. 83, 601-606 (1994).
14. Meng F, Engbers GHM, Feijen J: Polyethylene glycol-grafted polystyrene particles. J. Biomed. Mater. Res. A70, 49-54 (2004).
15. Gaur U, Sahoo SK, De TK, Ghosh PC, Maitra A, Ghosh PK: Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system. Int. J. Pharm. 202, 1-10 (2000).
16. Arias JL, Gallardo V, Gómez-Lopera SA, Plaza RC, Delgado AV: Synthesis and characterization of poly(ethyl-2-cyanoacrylate) nanoparticles with a magnetic core. J. Control. Rel. 77, 309-321 (2001).
17. Hu FX, Neoh KG, Kang ET: Synthesis and in vitro anti-cancer evaluation of tamoxifen-loaded magnetite/PLLA composite nanoparticles. Biomaterials 27, 5725-5733 (2006).
18. Meyers PH, Cronic F, Nice CM: Experimental approach in the use and magnetic control of metallic iron particles in the lymphatic and vascular system of dogs as a contast and isotopic agent. Am. J. Roentgenol. Radium Ther. Nucl. Med. 90, 1068-1077 (1963).
19. Hilal SK, Michelsen WJ, Driller J, Leonard E: Magnetically guided devices for vascular exploration and treatment. Radiology 113, 529-540 (1974).
20. Widder KJ, Senyei AE, Ranney DF: Magnetically responsive microspheres and other carriers for the biophysical targeting of antitumour agents. Avd. Pharmacol. Chemother. 16, 213-217 (1979).
21. Kato T, Nemoto R, Mori H: Magnetic microcapsules for targeted delivery of anticancer drugs. Appl. Biochem. Biotechnol. 10, 199-211 (1984).
22. Gupta PK, Hung CT, Rao NS: Ultrastructural disposition of adriamycinassociated magnetic albumin microspheres in rats. J. Pharmacol. Sci. 78, 290-294 (1989).
23. Häfeli UO, Sweeney SM, Beresford BA, Sim EH, Macklis RM: Magnetically directed poly(lactic acid) 90Y-microspheres: novel agents for targeted intracavitary radiotherapy. J. Biomed. Mater. Res. 28, 901-908 (1994).
24. Häfeli UO, Sweeney SM, Beresford BA, Humm JL, Macklis RM: Effective targeting of magnetic radioactive 90Y-microspheres to tumor cells by an externally applied magnetic field. Preliminary in vitro and in vivo results. Nucl. Med. Biol. 22, 147-155 (1995).
25. Lübbe AS, Bergemann C, Huhnt W et al.: Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res. 56, 4694-4701 (1996).
26. Lübbe AS, Bergemann C, Riess H et al.: Clinical experiences with magnetic drug targeting: a Phase I study with 4′-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res. 56, 4686-4693 (1996).
27. Pankhurst QA, Connolly J, Jones SK, Dobson J: Applications of nanoparticles biomedicine. J. Phys. D Appl. Phys. 36, R167-R181 (2003).
28. Rudge S, Peterson C, Vessely C et al.: Adsorption and desorption of chemotherapeutic drugs from a targeted carrier (MTC). J. Control. Rel. 74, 335-340 (2001).
29. Preiss J, Link KH, Schmoll E: Prinzipien der lokoregionären therapie. In: Kompendium Internistische Onkologie. Part I. Schmoll HJ, Hoffken K, Possinger K (Eds). Springer, Berlin, Germany, 873-880 (1999).
30. Ito T, Machida Y, Sannan T, Nagai T: Magnetic granules: a novel system for specific drug delivery to esophageal mucosa in oral administration. Int. J. Pharm. 61, 109-117 (1990).
31. Arias JL, Gallardo V, Ruiz MA, Delgado AV: Magnetite/ poly(alkylcyanoacrylate) (core/shell) nanoparticles as 5-fluorouracil delivery systems for active targeting. Eur. J. Pharm. Biopharm. 69, 54-63 (2008).
32. Cooke JWB, Bright R, Coleman MJ, Jenkins KP: Process research and development of a dihydropyrimidine dehydrogenase inactivator: large-scale preparation of enuracil using a sonogashira coupling. Org. Process Res. Dev. 5, 383-386 (2001).
33. Merle P, Si-Ahmed S, Habersetzer F et al.: Phase I study of intra-arterial hepatic (IAH) delivery of doxorubicin-transdrug (DT) for patients with advanced hepatocellular carcinoma (HCC). J. Clin. Virol. 36, S179 (2006).
34. Scheel V, Die J: Intraarterielle chemotherapie. In: Oto-Rhino- Laryngologie in Klinik und Praxis. Naumann HH, Helms J, Herberhold J, Kastenbauer E (Eds). Thieme, Stuttgart, Germany, 457 (1998).
35. Häfeli UO, Pauer GJ, Roberts WK, Humm JL, Macklis RM: In: Scientific and Clinical Applications of Magnetic Carriers. Häfeli U, Schutt W (Eds). Plenum Publishing Corp., NY, USA, 501 (1997).
36. Balkwill DL, Maratea D, Blakemore RB: Ultrastructure of a magnetic spirillum. J. Bacteriol. 141, 1399-1408 (1980).
37. Grunberg K, Muller EC, Otto A et al.: Biochemical and proteomic ana lysis of the magnetosome membrane in Magnetospirillum gryphiswaldense. Appl. Environ. Microbiol. 70, 1040-1050 (2004).
38. Matsunaga T, Kamiya S: Use of magnetic particles isolated from magnetotactic bacteria for enzyme immobilization. Appl. Environ. Microbiol. 26, 328-332 (1987).
39. Ota H, Takeyama H, Nakayama H et al.: SNP detection in transforming growth factor-b1 gene using bacterial magnetic particles. Biosens. Bioelectron. 18, 683-687 (2003).
40. Matsunaga T, Ueki F, Obata K et al.: Fully automated immunoassay system of endocrine disrupting chemicals using monoclonal antibodies chemically conjugated to bacterial magnetic particles. Anal. Chim. Acta 475, 75-83 (2003).
41. Sun JB, Duan JH, Dai SL et al.: In vitro and in vivo antitumor effects of doxorubicin loaded with bacterial magnetosomes (DBMs) on H22 cells: the magnetic bio-nanoparticles as drug carriers. Cancer Lett. 258, 109-117 (2007).
42. Neuberger T: Doctoral thesis. University of Zurich, Switzerland (2002).
43. Zavisova V, Koneracka M, Strbak O et al.: Encapsulation of indomethacin in magnetic biodegradable polymer nanoparticles. J. Magn. Magn. Mater. 311, 379-382 (2007).
44. Gonda I: Preface. Major issues and future prospects in the delivery of therapeutic and diagnostic agents to the respiratory tract. Adv. Drug Deliv. Rev. 5, 1-9 (2000).
45. Ally J, Martin B, Khamesee MB, Roa W, Amirfazli A: Magnetic targeting of aerosol particles for cancer therapy. J. Magn. Magn. Mater. 293, 442-449 (2005).
46. Lacava LM, Lacava ZGM, Azevedo RB et al.: Use of magnetic resonance to study biodistribution of dextran-coated magnetic fluid intravenously administered in mice. J. Magn. Magn. Mater. 252, 367-369 (2002).
47. Primo FL, Michieleto L, Rodrigues MAM et al.: Magnetic nanoemulsions as drug delivery system for Foscan: skin permeation and retention in vitro assays for topical application in photodynamic therapy (PDT) of skin cancer. J. Magn. Magn. Mater. 311, 354-357 (2007).
48. Mitchell D, Cohen M: MRI Principles. Saunders, PA, USA (2004).
49. Corot C, Robert P, Idee JM, Port M: Recent advances in iron oxide nanocrystal technology for medical imaging. Adv. Drug Deliv. Rev. 58, 1471-1504 (2006).
50. Gillis P, Koenig SH: Transverse relaxation of solvent protons induced by magnetized spheres: application to ferritin, erythrocytes, and magnetite. Magn. Reson. Med. 5, 323-345 (1987).
51. Weissleder R, Bogdanov A, Neuwelt EA, Papisov M: Long-circulating iron oxides for MR imaging. Adv. Drug Deliv. Rev. 16, 321-334 (1995).
52. Stark DD, Weissleder R, Elizondo G et al.: Long-circulating iron oxides for MR imaging. Radiology 168, 297-301 (1988).
53. Wang YX, Hussain SM, Krestin GP: Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur. Radiol. 11, 2319-2331 (2001).
54. Morales MP, Bomati-Miguel O, Pérez de Alejo R, Ruiz-Cabello J, Veintemillas-Verdaguer S, O'Grady K: Contrast agents for MRI based on iron oxide nanoparticles prepared by laser pyrolysis. J. Magn. Magn. Mater. 266, 102-109 (2003).
55. Harisinghani MG, Barentsz J, Hahn PF et al.: Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N. Engl. J. Med. 348, 2491-2499 (2003).
56. Bulte JW, Kraitchman DL: Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. NMR Biomed. 17, 484-499 (2004).
57. Schellenberger EA, Sosnovik D, Weissleder R, Josephson L: Magneto/optical annexin V, a multimodal protein. Bioconjug. Chem. 15, 1062-1067 (2004).
58. Sosnovik DE, Weissleder R: Emerging concepts in molecular MRI. Curr. Opin. Biotechnol. 18, 4-10 (2007).
59. Ikeda N, Hayashida O, Kameda H, Ito H, Matsuda T: Experimental study on thermal damage to dog normal brain. Int. J. Hyperthermia 10, 553-561 (1994).
60. Wada S, Yue L, Tazawa K et al.: New local hyperthermia using dextran magnetite complex (DM) for oral cavity: experimental study in normal hamster tongue. Oral Dis. 7, 192-195 (2001).
61. Jordan A, Wust P, Fahling H, John W, Hinz A, Felix R: Inductive heating of ferrimagnetic particles and magnetic fluids: physical evaluation of their potential for hyperthermia. Int. J. Hyperthemia 9, 51-68 (1993).
62. Ma M, Wu Y, Zhou J, Sun Y, Zhang Y, Gu N: Size dependence of specific power absorption of Fe3O4 particles in AC magnetic field. J. Magn. Magn. Mater. 268, 33-39 (2004).
63. Hergta R, Hiergeista R, Zeisberger M et al.: Enhancement of AC-losses of magnetic nanoparticles for heating applications. J. Magn. Magn. Mater. 280, 358-368 (2004).
64. Vonk GP, Schram JL: Dual-enzyme cascade-magnetic separation immunoassay for respiratory syncytial. J. Immunol. Methods 137, 133-139 (1991).
65. Wang X, Lin JM, Ying XT: Evaluation of carbohydrate antigen 50 in human serum using magnetic particle-based chemiluminescence enzyme immunoassay. Anal. Chim. Acta 598, 261-267 (2007).
66. Buijs J, Lichtenbelt JWT, Norde W, Lyklema J: Adsorption of monoclonal IgGs and their F(ab)2 fragments onto polymeric surfaces. Colloids Surf. B Biointerfaces 5, 11-23 (1995).
67. Dittmer WU, de Kievit P, Prins MWJ, Vissers JLM, Mersch MEC, Martens MFWC: Sensitive and rapid immunoassay for parathyroid hormone using magnetic particle labels and magnetic actuation. J. Immunol. Methods 338, 40-46 (2008).
68. Safarik I, Safarikova M: Magnetic nanoparticles and biosciences. Monatsh. Chem. 133, 737-759 (2002).
69. Shimizu K, Ito A, Arinobe M et al.: Effective cell-seeding technique using magnetite nanoparticles and magnetic force onto decellularized blood vessels for vascular tissue engineering. J. Biosci. Bioeng. 103, 472-478 (2007).
70. Ito A, Hayashida M, Honda H et al.: Construction and harvest of multilayered keratinocyte sheets using magnetite nanoparticles and magnetic force. Tissue Eng. 10, 873-880 (2004).
71. Ito A, Hibino E, Honda H et al.: A new methodology of mesenchymal stem cell expansion using magnetic nanoparticles. Biochem. Eng. J. 20, 119-125 (2004).
72. Ito A, Hibino E, Kobayashi C et al.: Construction and delivery of tissue-engineering human retinal pigment epithelial cell sheets using magnetite nanoparticles and magnetic force. Tissue Eng. 11, 489-496 (2005).
73. Kemmner W, Moldenhauer G, Schlag P, Brossmer R: Separation of tumor cells from a suspension of dissociated human colorectal carcinoma tissue by means of monoclonal antibodycoated magnetic beads. J. Immunol. Methods 147(2), 197-200 (1992).
74. Kronick P, Gilpin RW: Use of superparamagnetic for isolation of cells. J. Biochem. Biophys. Methods 12, 73-80 (1986).
75. Safarik I, Safarikova M: Use of magnetic techniques for isolation of cells. J. Chromatogr. B Biomed. Sci. Appl. 722, 33-35(1999).
76. Häfeli U, Schütt W, Teller J, Zborowski M: Scientific and Clinical Applications of Magnetic Carriers. Plenum Press, NY, USA (1997).
77. Saiyed ZM, Telang SD, Racnchand CN: Application of magnetic techniques in the field of drug discovery and biomedicine. Biomagn. Res. Technol. 1, 23-33 (2003).
78. Schneider S, Rusconi S: Magnetic selection of transiently transfected cells. Biotechniques 21, 876 (1996).
79. Nagatani N, Shinkai M, Honda H, Kobayashi T: Development of a new transformation method using magnetite cationic liposomes and magnetic selection of transformed cells. Biotechnol. Tech. 12, 525-528 (1998)
80. Yoshida H, Kataoka T: Adsorption of BSA on cross-linked chitosan - the equilibrium isotherm. Chem. Eng. J. Biochem. Eng. J. 41(1), B11-B15 (1989).
81. Honda H, Kawabe A, Skinkai M, Kobayashi T: Recovery of recombinant Escherichia coli by chitosan-conjugated magnetite. Biochem. Eng. J. 3(2), 157-160 (1999).
82. Scherer F, Anton M, Schillinger U et al.: Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther. 9(2), 102-109 (2002).
83. Goodwin SC, Bittner CA, Peterson CL, Wong G: Single dose toxicity study of hepatic intra-arterial infusion of doxorubicin coupled to a novel magnetically targeted drug carrier. Toxicol. Sci. 60(1), 177-183 (2001).
84. Krotz F, de Wit C, Sohn HY et al.: Magnetofection potentiates gene delivery to cultured endothelial cells. Mol. Ther. 7, 700-710 (2003).
85. Plank C, Schillinger U, Scherer F et al.: The magnetofection method: using magnetic force to enhance gene delivery. Biol. Chem. 384 (5), 737-747 (2003).
86. Hirao K, Sugita T, Kubo T et al.: Targeted gene delivery to human osteosarcoma cells with magnetic cationic liposomes under a magnetic field. Int. J. Oncol. 22, 1065-1071 (2003).
87. Zheng X, Lu J, Deng L, Xiongc Y, Chena J: Preparation and characterization of magnetic cationic liposome in gene delivery. Int. J. Pharm. 366, 211-217 (2009).
88. Pileni MP: Reverse micelles as microreactors. J. Phys. Chem. 97, 6961-6973 (1993).
89. Xu C, Sun S: Monodisperse magnetic nanoparticles for biomedical applications. Polym. Int. 56, 821-826 (2007).
90. Rockenberger J, Scher JEC, Alivisatos AP: A new nonhydrolytic single-precursor approach to surfactant-capped nanocrystals of transition metal oxides. J. Am. Chem. Soc. 121, 11595-11596 (1999).
91. Tartaj P, Morales M, Veintemillas-Verdaguer S, Gonzalez-Carreno T, Serna CJ: The preparation of magnetic nanoparticles for application in biomedicine. J. Phys. D Appl. Phys. 36, R182-R197 (2003).
92. Decher G, Fuzzy G: Nanoassemblies: toward layered polymeric multicomposites. Science 277, 1232-1237 (1997).
93. Caruso F, Spasova M, Susha M: Magnetic nanocomposite particles and hollow spheres constructed by a sequential layering approach. Chem. Mater. 13, 109-116 (2001).
94. Tissue engineering with nanomagnets www.nanowerk.com/spotlight/ spotid=9811.php
95. Magnetic nanoparticles detect and remove harmful bacteria www.sciencedaily.com/ releases/2007/11/071119110910.htm
96. Small Times www.smalltimes.com
97. Knamori I, Seko M, Yokota H: JP 05345022 [93345022] 7 (1993).
98. Massart R: US4329241 (1982).